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Two controlled studies were undertaken to assess the efficacy of streptomycin 1 g. or
0.75 g. (by random allocation) plus isoniazid 15 mg./kg. body-weight once-weekly (the
SHOW regimen) in the prevention of bacteriological relapse over a 4 year period, in
patients with quiescent pulmonary tuberculosis at the end of one year of chemotherapy.
In the first study which involved patients with residual cavitation at one year, bacterio-
logical relapse requiring treatment occurred in 3 per cent of 87 patients given the
SHOW regimen for 12 months as compared with 21 per cent of 94 patients on a
placebo, a high proportion of the relapses in the latter occurred in the 2nd year and
with sensitive organisms.In the second study on patients with no residual cavitation
at one year, relapse requiring treatment occurred in 2 per cent of 98 patients given
the SHOW regimen for 6 months as compared with 1 per cent of 90 patients given
isoniazid approximately 4.5 mg./kg. daily for 12 months.
Previous reports from the Tuberculosis Chemotherapy Centre1,2 have shown
that maintenance therapy with isoniazid alone was highly effective in preventing
relapse if given for 1 year in a dose of 150-200 mg. daily to patients with bacteriologi-
cally quiescent disease and without residual cavitation at the end of 1 year of initial
chemotherapy; also when given for 6 months, a larger dose of 300 mg. daily was
not so effective.Further, in patients with quiescent disease and with residual cavita-
tion, isoniazid, even in a dosage of 400 mg. daily for 12 months was not satisfactory.
Two controlled studies were, therefore, conducted to investigate the efficacy of main-
tenance chemotherapy with a once-weekly regimen of streptomycin plus high dosage
isoniazid (SHOW) for 6 months (i.e. chemotherapy for a total of 18 months includ-
ing 12 months of initial chemotherapy) in patients without residual cavitation at 1 year
and for 12 months (i.e. total period of 24 months) in patients with residual cavitation.
Patients in both studies were followed-up for a period of 4 years and the findings are
presented in this report.
Material and Methods
This report is based on 369 patients with bacteriologically confirmed pulmonary
tuberculosis with drug sensitive organisms who had attained bacteriologically quiescent
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disease at 1 year (all of 7-9 cultures at 10, 11 and 12 months being negative). On initial
admission, 56 per cent were between 25 and 46 years, the mean age being 33 years;
the mean weight was 39.0 kg. (range 19.5 to 69.1 kg.) and 67 per cent were males.In
the first year, all had received streptomycin (1 g. or 0.75 g. by random allocation) plus
isoniazid, twice-weekly in 75 patients, daily for 1 month followed by once-weekly
in 181, and once-weekly in 113; about a third had received PAS or pyrazinamide as a
third drug3,4. Each patient was classified at 1 year as having either residual cavitation,
or no residual cavitation, from postero-anterior radiographs and tomograms, and
allocated at random to treatment in the second year.
Patients with residual cavitation (181 patients)
(a) SHOW regimen (12 months) :Streptomycin 1 g. or 0.75 g. (as in the first year)
by intramuscular injection plus supervised oral isoniazid approximately 15 mg./kg.
body-weight* administered at the same time, once a week for 12 months (87 patients); or
(b) placebo (12 months) :One tablet of calcium gluconate 500 mg. self-administered
daily for 12 months (94 patients).
Patients with no residual cavitation (188 patients)
(a) SHOW regimen (6 months) :The above once-weekly regimen for 6 months
followed by the placebo for 6 months (98 patients); or
(b) isoniazid regimen (12 months) :Isoniazid alone in a single oral dose of
approximately 4.5 mg./kg. body-weight† daily, self-administered for 12 months
(90 patients).
Management of patients :In general, patients were treated as out-patients, the
SHOW patients attending the Centre once a week to receive their chemotherapy under
supervision and those on isoniazid alone or the placebo visiting monthly for a supply of
their tablets.
One sputum specimen was examined by smear and culture every month in the
second year while two specimens were examined every 3 months in subsequent years.
Two additional specimens were examined at 24 months, an additional specimen at 36
and 48 months and 3 additional specimens at 60 months.Thus, 14 specimens were
examined in the 2nd year, 9 each in the 3rd and 4th years, and 11 in the 5th year,
making a total of 43; additional specimens were examined if a patient produced a
positive culture.If a patient produced a positive culture at the 57th or the 60th
month, additional sputum specimens were examined for the next 6 months. Tests
* The dosages were 400 mg. for patients weighing below 30.0 kg. 600 mg. for patients weighing 30.0
to 44.9 kg. and 750 mg. for patients weighing 45.0 kg. or more; 6 mg. of pyridoxine was incorpora-
ted in each dose of isoniazid.
† The dosages were 150 mg. for patients weighing below 35.0 kg., 175 mg. for patients weighing 350
to 44.9 kg. and 200 mg. for patients weighng 45.0 kg. or more.
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for sensitivity to streptomycin and isoniazid were performed. The bacteriological
methods and the definitions of resistance employed have been described elsewhere3.
Bacteriological relapse and treatment :Bac eriological relapse is defined as the
occurrence of two or more positive cultures in any 6 month period. Re-treatment was
started only if : (a) the bacterial population was large, i.e., 2 or more positive cultures
in a 2 month period (at least one with 20 or more colonies), associated with a positive
smear, or (b) there was an unequivocal radiographic spread (confirmed by an indepen-
dent assessor) in the presence of positive sputum.
Results
Patients with residual cavitation at 1 year :All the 181 patients had positive cultures
at the time of admission to initial chemotherapy, the first collection specimen of
sputum being smear-positive in 93 per cent of the 87 patients on SHOW and in 87 per
cent of the 94 patients on placebo.Moderate, extensive or gross radiographic disease  
was present in 78 per cent and 79 per cent respectively.In each series, 34 per cent were
rapid inactivators of isoniazid.The proportions of patients who received twice-weekly,
daily followed by once-weekly, or once-weekly regimens in the first year were similar in
the SHOW and placebo series. At 1 year, in addition to residual cavitation, moderate
or extensive radiographic lesions were still present in 49 per cent of the SHOW and
53 per cent of the placebo patients.Thu , the two series were similar on admission to
the original treatment and at 1 year.Th  culture examination was also similar in the
two series in the next 4 years (40.6 cultures in the SHOW and 40.4 in the placebo
patients).
In the second year, 93 per cent of the SHOW patients received 75 per cent or
more of their scheduled 52 doses, 78 per cent received 90 per cent or more.Th  mean
percentage of doses received was 93.
Bacteriological relapse :A bacteriological relapse requiring treatment (Table)
occurred in 3 (3 per cent) SHOW patients (who had received 81 per cent, 92 per cent
and 98 per cent of the scheduled chemotherapy) and in 20 (21 per cent) placebo
patients (P=0.001).Two of the former and 15 of the latter had an unequivocal radio-
graphic deterioration also. Two patients on SHOW had received 1 g. streptomycin and
one had received 0.75 g.Relapse occurred in one patient on SHOW and 14 patients
on placebo in the second year; of these, the patient on SHOW and 10 of the placebo
group had relapse by the 15th month.
Of the 23 patients, 21 (3 SHOW, 18 placebo) relapsed with organisms sensitive to
isoniazid and streptomycin. One patient (placebo) had organisms resistant to both
drugs. The remaining (placebo) produced cultures resistant to streptomycin but
sensitive to isoniazid.
Four more patients (1 SHOW, 3 placebo) had a bacteriological relapse which
resolved spontaneously i.e., without re-treatment.The SHOW patient had relapse
in the 60th month with sensitive organisms.The 3 placebo patients had relapses at
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24, 39 and 60 months respectively.One had organisms resistant to isoniazid and sen-
sitive to streptomycin; the others had organisms sensitive to both the drugs.
Deaths : Of the patients who did not have a bacteriological relapse, 1 SHOW and 7
placebo patients died of non-tuberculous causes during the 4 year period. The
SHOW patient died suddenly of an unknown cause in the 29th month.He had been
consistently negative by smear and culture for 19 months before death.The plac bo
patients died in the 14th, 35th, 39th, 45th, 46th, 52nd and 58th months respectively.
They had been consistently negative by smear and culture for 11, 27, 34, 43, 43, 48 and
54 months respectively before death.The first two died of acute respiratory infections,
the 3rd of pyrexia of unknown origin, the 4th probably of old age, the 5th committed
suicide, the 6th died of an unknown cause in a maternity hospital in an advanced
stage of pregnancy, and the 7th in status asthmaticus.None of these patients showed
evidence of reactivation of tuberculosis.
Three (1 SHOW, 2 placebo) of the patients who had a relapse requiring treatment
subsequently died.The SHOW patient, who relapsed in the 31st month, did not res-
pond to re-treatment as he was extremely irregular in his drug intake, and died of tuber-
culosis in the 56th month with organisms sensitive to streptomycin and isoniazid.
One placebo patient died after a spontaneous pneumothorax in the 19th month, having
produced only negative cultures in the preceding month; the second, who had her
elapse in the 15th month, left Madras before re-treatment was completed, and died
in the 34th month, probably of tuberculosis.
No autopsies were performed.
Drug toxicity :One patient (female, aged 25 years) had the dosage of strepto-
mycin reduced from 0.75 g. to 0.5 g. in the 21 st month due to severe giddiness. Another
(SHOW-a slow inactivator of isoniazid) developed peripheral neuropathy in the 14th
month which responded to a pyridoxine supplement of 8 mg. daily, the SHOW regimen
being continued.
Factors of prognostic significance :The prognostic significance of various factors on
relapse requiring treatment was examined in the placebo series.The factor  studied
were age, sex, weight, isoniazid inactivation status, the smear grade and extent of
cavitation on admission to initial treatment, the total extent of radiographic lesion
on admission and at the start of the relapse study, the treatment regimen, the percentage
of chemotherapy received and the month of sputum conversion in the first year.
It was observed that the incidence of relapse requiring treatment was relatively
high in patients who had a heavy bacterial content of sputum on admission to initial
treatment and in patients who had a late sputum conversion.Thus, 26 per cent of 68
patients with a 3-plus or 2-plus smear initially had a relapse requiring treatment com-
pared with 8 per cent of 26 patients with a 1-plus or negative smear (P=0.04); 43 per
cent of 23 patients who had a sputum conversion at 4 months or later had a relapse
requiring treatment as compared with 14 per cent of 71 patients who had converted by
3 months (P<0.01). Multiple regression analysis involving all the factors showed
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that the only factor with a statistically significant prognostic value was the speed of
sputum conversion.
Patients with no residual cavitation at 1 year :All 188 patients had culture positive
disease on admission to (initial chemotherapy, the first collection specimen of sputum
being smear positive in 88 per cent of the 98 SHOW patients and 91 per cent of the
90 isoniazid patients.Cavitation was present initially in 95 per cent and 94 per cent
respectively, and moderate, extensive or gross radiographic disease in 57 per cent and
66 per cent respectively.The proportions of rapid inactivators were 31 per cent and
29 per cent respectively. The proportions of patients who received twice-weekly,
daily followed by once-weekly, or once-weekly regimens in the first year were similar
in the SHOW and isoniazid series.At 1 year, no residual radiographic lesion was
present in 5 per cent of the SHOW patients and 6 per cent of the isoniazid patients,
67 per cent in each series had trivial, slight or limited disease, and 28 per cent in each
series had moderate or extensive but non-cavitated lesions.Thus, the two series of
patients were similar on admission and at 1 year.They had a high and similar intensity
of bacteriological examination, the average number of cultures being 41.6 in the SHOW
and 40.8 in the isoniazid series during the 4 year period.
In the second year, 98 per cent of the SHOW patients received 75 per cent or
more of their scheduled 26 doses, including 85 per cent who received 90 per cent or
more. The mean percentage of doses received was 97. Each isoniazid patient was
given a month’s supply of isoniazid at a time for self-administration.The mean per-
centage of isoniazid collected was 98, 45 per cent having collected 100 per cent of
their doses.
Bacteriological relapse :A bacteriological relapse requiring treatment (Table)
occurred in 2 (2 per cent) SHOW patients, at 20 months (1 g. streptomycin) and 30
TABLE. BACTERIOLOGICAL RELAPSE DURING THE 4 YEAR PERIOD OF FOLLOW-UP RELATED T0
CAVITATION STATUS AT ONE YEAR AND TREATMENT DURING THE SECOND YEAR.
Cavitation Treatment Total
Patients who had a bacteriological relapse
requiring treatment
status at
one year
in the No. of
second year patients Year of relapse
No. %
Second Third Fourth Fifth
SHOW 87 3 3 1 1 0 1
Cavitated (12 months)
Placebo 94 20 21 14 1 1 4
SHOW 98 2 2 1 1 0 0
Non-cavitated (6 months)
Isoniazid 90 1 1 0 1 0 0
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months (0.75 g. streptomycin) respectively, and 1 (1 per cent) isoniazid patient, at 36
months, all 3 after the cessation of chemotherapy.Both the SHOW patients had
received 100 per cent of their scheduled chemotherapy and the isoniazid patient had
collected 100 per cent of his doses.On  SHOW patient had a strain resistant to
streptomycin and sensitive to isoniazid and the other had organisms sensitive to both
drugs; the isoniazid patient had a strain resistant to isoniazid but sensitive to strepto-
mycin. All the three also had clear cut radiographic deterioration.
Two other patients (1 SHOW, 1 isoniazid) had a bacteriological relapse, with drug
sensitive organisms, at 45 and at 60 months respectively, but their sputa reconverted
spontaneously.
Deaths : During the follow-up 5 SHOW and 3 isoniazid patients died, all of non-
tuberculous causes.The SHOW patients died in the 20th, 31st, 46th, 51st and 54th
months respectively. The first died of severe diarrhoea, the second suddenly, pro-
bably of a cardiac cause, the third of severe anaemia, the fourth of a massive haemo-
ptysis, and the fifth of an acute abdomen.Their sputa had been consistently negative
by smear and culture for 17, 27, 37, 47 and 53 months respectively before death.
The 3 isoniazid patients died in the 35th, 36th and 52nd months respectively. The
first two died of unknown causes, and the third probably of acute enteritis. Their
sputa had been consistently negative by smear and culture for 31, 31 and 48 months
respectively, before death.None of the patients showed evidence of reactivation of
tuberculosis.No autopsies were performed.
Drug toxicity :Four SHOW (2 slow, 2 rapid inactivators) and 5 isoniazid (4 slow, 1
rapid) patients had symptoms suggestive of peripheral neuropathy.Seven patients
(2 SHOW, of whom 1 was a slow inactivator, and 5 isoniazid, of whom 4 were slow
inactivators) were given vitamin B complex tablets containing pyridoxine. The
remaining 2 were not given any symptomatic treatment. None of the 9 patients
complained subsequently.One SHOW patient had facial paraesthesia which could be
controlled by antihistamines.All 10 patients had their maintenance chemotherapy
without interruption.
Discussion
Although in the last few years short course chemotherapy has been studied and
effective regimens identified5,6 the regimens currently being introduced into clinical
practice include expensive drugs such as rifampicin and pyrazinamide. Further,
these drugs are not readily available in many developing countries and hence the regi-
mens may be inapplicable in service programmes.It ther fore still remains important
to investigate duration of conventional chemotherapeutic regimen with the currently
available drugs, and maintenance regimens for the prevention of relapse.
The present studies demonstrate the value of the SHOW regimen (streptomycin
plus isoniazid once a week) when given for 12 months to patients with bacteriologically
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quiescent disease and with residual cavitation, and for 6 months to those without
residual cavitation,Thus, only 3 per cent of patients with residual cavitation who
received it relapsed, in contrast to 21 per cent on a placebo (P=0.001); the protection
obtained (84 per cent) is highly satisfactory.In an earlier study2 when isoniazid
alone in a dose of 400 mg. daily was given for 1 year as maintenance chemotherapy
to patients with residual cavitation, the protection obtained was 54 per cent.
In patients with non-cavitated quiescent disease at 12 months, 2 per cent of the
SHOW patients had a relapse compared with 1 per cent of patients who received
isoniazid daily for 12 months.In this respect it is relevant that in an earlier study in
the Centre2 the relapse rate in patients with non-cavitated disease without maintenance
chemotherapy was 12 per cent.
The SHOW regimen requires only once-weekly attendance.As it is fully super-
vised, the amount of chemotherapy actually received by the patients is known precisely
and if doses are missed, defaulter action can be instituted immediately.The r g m n is
highly effective, is relatively inexpensive where facilities for giving injections already
exist, and toxicity is low.In view of these advantages, a shorter duration of main-
tenance chemotherapy with the regimen is now being studied.
In many rural areas of the developing countries, regimens containing strepto-
mycin will not be readily applicable because of the lack of injection facilities. Hence,
the efficacy of a fully supervised once-weekly oral regimen of PAS plus isoniazid is
now under study at this Centre.
Acknowledgment
The authors acknowledge the valuable efforts of the entire staff of the Centre,
particularly the public health nurses, social workers, and health visitors in obtaining
complete data.Dr. K.S. Sanjivi and Dr. K.V. Krishnaswami deserve thanks for
undertaking radiographic assessments.These studies were carried out under the joint
auspices of the Indian Council of Medical Research, the Government of Tamil Nadu
and the World Health Organization, in collaboration with the Medical Research Council
of Great Britain.
References
1. Evans, C., Devadatta, S., Fox, W., Gangadharam, P.R.J., Menon, N.K., Ramakrishna, C.V.,
Sivasubramanian, S., Somasundaram, P.R., Stott, H. and Velu, S. A 5 year study of patients
with pulmonary tuberculosis treated at home in a controlled comparison of isoniazid plus PAS
with 3 regimens of isoniazid alone. Bull WHO 41 (1969) 1.
2. Nazareth, O., Devadatta, S., Fox, W., Menon, N.K., Radhakrishnan, S., Rajappa, D., Ramakrishnan,
C.V., Somasundaram, P.R., Stott, H., Subbammal, S. and Velu, S. Two controlled studies of the
efficacy of isoniazid alone in preventing relapse in patients with bacteriologically quiescent
pulmonary tuberculosis at the end of one year of chemotherapy.Bull WHO 45 (1971) 603.
8 SHOW regimen for preventing relapse of pulmonary tuberculosis
3. Tuberculosis Chemotherapy Centre, Madras.A controlled comparison of a twice-weekly and
three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull WHO 43
(1970) 143.
4.       A  con t ro l l ed  compar i son  o f  the  two  fu l l y  super -
vised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis. Tubercle
54 (1973) 23.
5. East African/British Medical Research Council. Third report. Controlled clinical trial of four
short course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Lancet ii (1974) 237.
6. Hong Kong Tuberculosis Treatment Services/British Medical Research Council.Contr lled trial
of 6 and 9 month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide
for pulmonary tuberculosis in Hong Kong.Tubercle 56 (1975) 81.
